Tau-first and amyloid-first AD subtypes identified

New findings have added to the weight of evidence suggesting that some Alzheimer’s disease (AD) patients develop early-stage tau pathology before amyloid pathology.

Researchers from centers in London, UK, and Amsterdam, the Netherlands, used data from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) to perform two analyses. They applied data-driven disease subtyping models to positron emission tomography (PET) and cerebrospinal fluid (CSF) measures of both amyloid and tau.

Vuoi saperne di più?

Accedi o registrati per accedere a tutti i contenuti di Neurodiem.

Hai già un account? Accedi

Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.

No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.